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compartments [7]. Very recently, these cell maturational stages
have been characterized in great detail in terms of the likes of
morphology, ploidy, proliferation, biochemistry and gene expres-
sion [8]. Moreover, our own recent studies in the human liver,
demonstrating a portal tract to hepatic vein orientation of groups
of clonally-derived hepatocytes, are in line with the concept of a
dynamic lineage system [9]. On the other hand, not all studies
have concurred with this concept, for example Bralet and col-
leagues [10] genetically labeled rat hepatocytes in vivo at 24 h
after partial hepatectomy, but failed to observe any change in
their location (periportal and mid-zonal) over the proceeding
15 months – observations not consistent with a ‘streaming’
liver.
There are recent examples of the fairly long-term beneﬁcial
effects of HTx and survival of engrafted cells, for example, a
Crigler-Najjar patient survived well for 4 years after HTx before
an OLT and he still had conjugated bilirubin in his blood at
3.5 years [11]. In 2006, Sokal’s group performed a HTx for the
correction of argininosuccinate lyase deﬁciency, and cell track-
ing conﬁrmed their durable presence (12.5%) in the liver at
7 months after the last infusion [12]. More recent information
on that same case conﬁrmed that the patient was still doing
well at up to 18 months when she received an OLT [13]. On
the other hand, the majority of children undergoing HTx for
urea cycle disorders have only been monitored for a relatively
short time before OLT, though one 3-year-old patient with cit-
rullinemia was still doing well 30 months after HTx [14]. Many
other cases of HTx have also only provided short-term beneﬁt
including glycogen storage disease type I [15], and factor VII
deﬁciency [16].
In most studies, the absence of a sustained beneﬁt of HTx in
the medium to long-term has been ascribed to rejection
(‘wipe-out’) or other causes not directly related to HTx itself
(e.g. infections), but we would like to suggest that hepatocyte
egress (‘wash-out’) could be an alternative, but non-exclusive
explanation. We believe it is beholden upon hepatologists to once
and for all establish the cell replacement dynamics of the liver,
preferably in a large animal model. If the ‘streaming liver’
hypothesis wins the day then attempts at the correction of
metabolic liver disease should be directed towards targeting
cholangiocytes and/or other hepatocyte progenitors or only
transplanting hepatocytes into extrahepatic sites.
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JOURNAL OF HEPATOLOGYTo the Editor:
We have read with interest the review by Vallet-Pichard et al.
published in a recent issue of the Journal [1]. In the section ‘‘Recom-
mendation for HBV therapy’’ they reviewed the scarce data pub-
lished on this topic. They cited the article published by Kamar
et al. as the only experience with NUC therapy in renal transplan-Journal of Hepatology 20tation [2].We have published our experience with entecavir treat-
ment in a small population of chronic HBV patients with chronic
kidney disease [3]. Eleven male patients – 1 with stage 4 chronic
kidney disease, 7 undergoing hemodialysis in the waiting list for
a transplant, and 3 kidney transplanted recipients –were included
in the study evaluation. Six were treatment naïve, and 5 were12 vol. 56 j 993–999 997
lamivudine resistant. Entecavir was administered at a dose of 0.1–
1 mg qd according to the patients’ renal function. Nine out of 11
patients were HBeAg(+)/antiHBe(), the remaining 2 being
HBeAg()/antiHBe(+). After a median treatment of 2 ± 0.86 years,
entecavir therapy was associated with a signiﬁcant decrease in
serum HBV DNA levels in treated patients: HBV-DNA dropped
from 6.84 ± 1.45 log10 IU/ml (range 5.21–9.04) at baseline to
1.73 ± 2.11 log10 IU/ml (range0.78–4.72) at the timeof evaluation.
HBV DNA became undetectable in 6/11 treated patients (54.5%).
The rate of antiHBe seroconversionwas 77.7% (7/9HBeAg-positive
patients) (Table 1). There were no signiﬁcant changes in renal
function or hematological parameters.
Although this is a small cohort of patients, our results suggest
that long-term treatment with entecavir in HBV-positive kidney
transplanted patients or candidates for kidney transplantation,
appears to be safe and effective. This small experience add infor-
mation, and conﬁrms the recommendation of the recently pub-
lished international guidelines [4,5].
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Table 1. Baseline characteristics and results obtained with treatment.
Patient Renal 
status
Metavir
score
Baseline
HBeAg
status
Baseline HBV
DNA levels (IU/ml)
ETV Doses
mg/d
ETV treatment 
duration (yr)
HBV DNA 
at evaluation
HBsAg/HBeAg status
at evaluation
1 KT A3 F3 Positive 6872,852 0.5 2.68 3.02 log reduction AntiHBe seroconversion
2 KT A2 F2 Positive 7840,206 1 2.62 3.22 log reduction Unchanged
3 HD A3 F3 Positive 640,000,000 0.05 2.37 Undetectable AntiHBe seroconversion
4 HD A1 F1 Positive 240,000 0.1 3.27 Undetectable AntiHBe seroconversion
5 KT A3 F4 Positive 1100,000,000 0.5 1.06 7.14 log reduction AntiHBe seroconversion
6 ESRD n.d. Positive 640,000,000 0.15 2.39 Undetectable AntiHBs and antiHBe 
seroconversion
7 HD n.d. Negative 291,000 0.05 1.52 Undetectable Unchanged
8 HD n.d. Positive 13,700,000 0.05 0.68 2.41 log reduction Unchanged
9 HD A3 F4 Positive 326,460 0.1 0.63 0.78 log reduction AntiHBe seroconversion
10 HD n.d. Positive 164,955 0.1 2.15 Undetectable AntiHBe seroconversion
11 HD A3 F3 Negative 687,285 0.1 2.29 Undetectable Unchanged
KT, kidney transplant, HD, hemodialysis, ESRD, end stage renal disease, n.d., not done.
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